NextCure and Simcere Zaiming presented positive Phase 1 data for SIM0505, an antibody drug conjugate targeting CDH6, showing a 55% objective response rate in heavily pretreated gynecologic cancer patients, including 52.9% in ovarian cancer and 66.7% in uterine serous carcinoma. The drug demonstrated favorable safety and tolerability, supporting ongoing dose optimization focused on platinum-resistant ovarian cancer. These results highlight SIM0505's potential as a new treatment option for difficult-to-treat gynecologic cancers, with plans for further pivotal studies.
Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...
Worldline has announced a conference call to discuss its H1 2026 financial results on July 30, 2026, at 6:30 pm CET. The event will be accessible via webcast, and sell-side analysts can participate in a Q&A session by pre-registering. The press relea...
Ipsen Pharma conducted a share buy-back program from July 6 to July 10, 2026, repurchasing a total of 28,541 shares. The average purchase price during this period was €166.05 per share. This buy-back activity reflects Ipsen's strategy to manage its c...
Ipsen Pharma conducted share buybacks from July 6 to July 10, 2026, purchasing a total of 28,541 shares. The average purchase price was €166.05 per share. These buybacks were made under Article 5 of the MAR regulation, indicating a structured repurch...
Barclays increased its price target for Hudbay Minerals to $32 from $30, citing strong growth prospects in copper mining. Despite a recent nearly 30% stock pullback due to market sentiment, Hudbay maintains a solid financial position with near-zero n...
